Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in SwitzerlandAndrea Favre-Bulle, Arjun Bhadhuri|PharmacoEconomics - Open|2023Cited by 13